SCHEMBL5203092

SCHEMBL5203092

CNS(=O)(=O)c1cc(O)ccc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.55
LMNA P02545 3/20 0.54
HSD17B10 Q99714 3/20 0.54
HPGD P15428 2/20 0.54
HIF1A Q16665 2/20 0.54
GAA P10253 4/20 0.50
POLB P06746 2/20 0.50
GFER P55789 2/20 0.50
ALDH1A1 P00352 4/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
PKM P14618 1/20 0.49
ALPL P05186 1/20 0.49
ALPI P09923 1/20 0.49
ALPG P10696 1/20 0.49
DNMT1 P26358 1/20 0.49
MCL1 Q07820 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
TSHR P16473 1/20 0.45
FTO Q9C0B1 1/20 0.45
ALOX15 P16050 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13287012 0.83 PTGS1 (0.59) PTGS1LMNAHSD17B10HPGDHIF1A
SCHEMBL743630 0.82 LMNA (0.65) LMNAHSD17B10HPGDHIF1AGAA
SCHEMBL10868958 0.82 GAA (0.48) LMNAGAAALDH1A1L3MBTL1TDP1
SCHEMBL32664450 0.82 GAA (0.48) LMNAGAAALDH1A1L3MBTL1TDP1
SCHEMBL25341310 0.81 WDR5 (0.56)
SCHEMBL17779262 0.81 PDE10A (0.44) LMNAHSD17B10HPGDHIF1AGAA
SCHEMBL6835906 0.81 P2RX1 (0.54) LMNAHSD17B10HPGDHIF1AGAA
SCHEMBL30519334 0.81 WDR5 (0.56)
SCHEMBL14958763 0.78 LMNA (0.50) LMNAGAAPOLBGFERALDH1A1
SCHEMBL32664305 0.77 KAT6A (0.46) LMNAHSD17B10HPGDHIF1AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242083-B1 PHENOXYPROPANOLAMINES, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI AVENTIS (FR) 2007-03-14 EP disclosed
US-6867220-B2 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them SANOFI-SYNTHELABO (FR) 2005-03-15 US disclosed
US-20030040530-A1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them SANOFI-AVENTIS (FR) 2003-02-27 US disclosed
EP-1242083-A1 PHENOXYPROPANOLAMINES, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Sanofi-Aventis (FR) 2002-09-25 EP disclosed
WO-2001043744-A1 PHENOXYPROPANOLAMINES, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI-SYNTHELABO (FR) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040530-A1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them CNR1, CORO1C, CBR1 PTGS1 2135/4885LMNA 865/4885HSD17B10 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.